Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trialAchim Rittmeyer, David R. Gandara, Fortunato Ciardiello et al.|The Lancet|2016Cited by 4.8k
Systematic Evaluation of Rheumatoid Arthritis Risk by Integrating Lifestyle Factors and Genetic Risk ScoresXinghao Yu, Fei‐Yan Deng, Bo Lin et al.|Frontiers in Immunology|2022Cited by 15